Stablecoin Development Corporation · AMEX:SDEV

Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (December 2016)

39 slides from Stablecoin Development's investor presentation, December 2016

  1. Slide 1: Going Beyond Antibiotics

    Going Beyond Antibiotics® Developing and Commercializing Anti‐Infective Products that Fight Infections without Giving Rise to Resistance December, 2016 NYSE MKT: NBY www.novabay.com

  2. Slide 2: Forward-Looking Statements

    Forward‐Looking Statements This presentation contains forward‐looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”

  3. Slide 3: Mark Sieczkarek - Background

    Mark Sieczkarek‐Background  35 years in the Life Sciences‐ Large and Small Companies  Pharmaceutical, Consumer, Diagnostics and Medical Devices  Finance  Sales & Marketing  Manufacturing  Mergers and Acquisitions  General Management  Bristol‐Myers‐Senior Vice‐President  Sanofi‐COO of US Dia

  4. Slide 4: Neutrophils – Our first line of defense against infections

    Neutrophils – Our first line of defense against infections Produce broad spectrum antimicrobials that do not give rise to resistance Pathogen Neutrophil Red Blood Cells 4

  5. Slide 5: The Foundation of NovaBay Technology

    The Foundation of NovaBay Technology Develop Anti‐Microbial Molecules that Mimic Those Produced by Neutrophils White Blood Cell Natural molecule: Natural Molecule: Hypochlorous Acid (HOCl) N‐Chlorotaurine (NCT) Fast Acting, broad spectrum anti‐microbial, difficult to mfg Longer Acting, Effective; BU

  6. Slide 6: Two Distinct Anti-Infective Product Groups

    Two Distinct Anti-Infective Product Groups Neutrox® Aganocides® Based Products Lead: Auriclosene® (FDA Cleared – Commercial) (Advanced Clinical) Urology UCBE (Urinary Catheter Blockage and Encrustation) WW: $700M WW: $600M 300,000 Chronically catheterized in U.S. 100,000 Chronic blockage • Paraplegi

  7. Slide 7: Going Beyond Antibiotics

    Going Beyond Antibiotics® Harnessing the Anti‐Infective Power of White Blood Cell Chemistry Developing and Commercializing Anti‐Infective Products that Fight Infections without Giving Rise to Resistance NYSE MKT: NBY www.novabay.com September 19, 2016

  8. Slide 8: NovaBay Pharmaceuticals

    NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market September 19, 2016 NYSE MKT: NBY www.novabay.com

  9. Slide 9: Strategic Focus on Eye Care

    Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa

  10. Slide 10: Anti-biofilm, Anti-Toxin, Does not generate resistance

    Does not ✓ generate Resistance ✓ Bacterial Removal ✓ Mechanical Debridement ✓ Anti‐biofilm Activity ✓ Anti‐Toxin 10

  11. Slide 11: 41 Million Potential Patients in U.S.

    41 Million Potential Patients in U.S. Blepharitis 24M Dry Eye 6M Contact lens Surgery ‐ Catarac intolerance 3M 4M Retinal injections Surgery ‐ Lasik 3M 1M 11

  12. Slide 12: What is Blepharitis?

    What is Blepharitis? Blepharon, Greek “eyelid” + itis – inflammatory disease  Signs and symptoms ‒ Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation  High incidence ‒ 37% of patients seen by ophthalmologists ‒ 47% of patients seen by optometrists  Most common cause is st

  13. Slide 13: Case Study – Compelling Results

    Case Study – Compelling Results with 13

  14. Slide 14: Only two Ingredients = Pure Hypochlorous Acid + Saline

    Only two Ingredients = 1. Pure Hypochlorous Acid + 2. Saline Oasis OCuSoft SteriLid Lid and Lash LIDCLENZ VisiCleanse Eye Scrub Water , PEG‐80 Sorbitan Water , PEG 80 , Sorbitan Water, Poloxamer, non‐foaming Water, Water USP Laurate , Sodium Laurate , Sodium Polyethylene, pH balanced Cocamidopropyl

  15. Slide 15: Growing Commercial Presence

    Growing Commercial Presence 15

  16. Slide 16: Avenova lid and lash hygiene

    Daily |& Lash Hygiene “Neu trox hal Pure Hypochorous

  17. Slide 17: Addressing Major U.S. Markets

    Addressing Major U.S. Markets 17

  18. Slide 18: Market Coverage

    Market Coverage 43 Direct Medical Reps In Key Metro Areas Northeast (11): Albany, Brooklyn, Manhattan, Nassau County, White Plains, Cherry Hill, Boston, Hartford, Patterson, Wash, DC, Philadelphia Midwestern (10): Chicago‐No, Chicago‐So, Detroit, St. Louis, Buffalo, St. Paul, Kansas City, KS, Clevel

  19. Slide 19: Covering Major Markets

    Covering Major Markets N™®vaBay PHARMA

  20. Slide 20: Net Sales ($000)

    Net Sales ($000) 3,088 2,578 1,003 33% Direct Buy & Bill Sales Prescriptions Sales 914 1,580 1,366 1,118 1,115 70% 2,085 67% 806 813 1,664 797 465 684 425 465 30% 553 321 40 122 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 20

  21. Slide 21: History of Net Operating Losses

    History of Net Operating Losses (in thousands) 500 Net Operating Loss ($000) ‐ Breakeven Adj Q3 for one‐time exps: (500) ‐ Move related ‐ Warrant repricing (1,000) (1,500) (1,697) (2,000) (2,013) (2,500) (2,843) (2,206) (2,982) (3,000) (3,487) (3,500) (3,786) (4,150) (4,078) (4,113) (4,000) (4,500)

  22. Slide 22: Avenova Phased Commercial Strategy

    Avenova Phased Commercial Strategy 22

  23. Slide 23: Avenova Phased Commercial Strategy

    Avenova Phased Commercial Strategy  Phase 1 – Initial Launch ‒ 2015 launch targeted two sales channels at introductory pricing 1. Sales Reps detailing directly to MD’s and OD’s ‐ Primary emphasis ‐ Most efficient approach to seed the market 2. Prescription sales ‐ Once doctors comfortable with prod

  24. Slide 24: Key Opinion Leader Endorsements

    Key Opinion Leader Endorsements 24

  25. Slide 25: KOL from Across U.S. Support

    KOL from Across U.S. Support Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, and >20 book chap

  26. Slide 26: KOLs from Across U.S. Support

    KOLs from Across U.S. Support Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry‐Eye – Ocular Surface Disease Center and serves as Director of Clinical Research. Internationally r

  27. Slide 27: Advertising and Collateral Marketing Materials

    Advertising Placements in Top Trade Journals Collateral Marketing Materials 27 27

  28. Slide 28: Interactive Website

    Interactive Website Find a Physician Find a Pharmacy 28

  29. Slide 29: Media Coverage Growing

    Media Coverage Growing 29

  30. Slide 30: Media Coverage Growing

    Media Coverage Growing Article: “Avenova With Neutrox Is ‘Breakthrough’ in Fight Against Contact Lens Intolerance” 30

  31. Slide 31: Media Coverage Growing

    Media Coverage Growing Article: “New Therapy Introduced for Chronic Dry Eye” 31

  32. Slide 32: Media Coverage Growing

    Media Coverage Growing Article: “Dry Eye: A Growing Problem in an Aging Population” 32

  33. Slide 33: Media Coverage Growing

    Media Coverage Growing Article: “New Treatments for Contact Lens Intolerance On The Rise” 33

  34. Slide 34: Media Coverage Growing

    Media Coverage Growing Article: “Did You Know Your Eye Makeup Could Be Making You Sick?” 34

  35. Slide 35: Media Coverage Growing

    Media Coverage Growing Article: “Spotlight on Demodex: Eliminating the Mite‐y Menace” 35

  36. Slide 36: Media Coverage Growing

    Media Coverage Growing RECEIVE THE OPTOMETRIC|OFFICE 9 [smtec SEARCH HOME ARCHIVES VIEWPOINTS DEPARTMENTS INSTRUMENTATION CONTACT LENSES THERAPEUTICS PATIENT CARE Issue Date: Optometric Office Mar 2016 p &@S Baa AN RX FOR HEALTHY LASHES AND LIDS Avenova provides long-term comfort for patients with c

  37. Slide 37: Financial Overview

    Financial Overview Million Market Cap (12/2/16) $60 Cash (9/30/16) $9.4 Debt $0 Shares Outstanding (Preliminary 9/30/16) 15 Shareholders Equity (9/30/16) $6.8

  38. Slide 38: Strategic Focus on Eye Care

    Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa

  39. Slide 39: NovaBay Pharmaceuticals

    NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market NYSE MKT: NBY www.novabay.com December, 2016

NovaBay Pharmaceuticals — Investor Presentation (December 2016) on 6ix